Paclitaxel
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Paclitaxel
- Generic name
- PACLITAXEL (AIBUMIN-BOUND)
- Manufacturer
- Ningbo Shuangcheng Pharmaceutical Co., Ltd
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 4df3fda6-0b29-420e-ab91-81441ce914ed
- SPL ID
- 83b2ce8a-e9d2-4227-94fd-7edf4f942cca
- Version
- 6
- Effective date
- 2026-06-10
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:02:17
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 216355 | derived:openfda.application_number |
| application number | ANDA216355 | openfda.application_number | |
| brand name | Paclitaxel | openfda.brand_name | |
| generic name | PACLITAXEL (AIBUMIN-BOUND) | openfda.generic_name | |
| manufacturer name | Ningbo Shuangcheng Pharmaceutical Co., Ltd | openfda.manufacturer_name | |
| ndc | package | 75007-041-01 | openfda.package_ndc |
| ndc | product | 75007-041 | openfda.product_ndc |
| ndc11 | package | 75007004101 | derived:openfda.package_ndc |
| rxcui | 583214 | openfda.rxcui | |
| spl id | 83b2ce8a-e9d2-4227-94fd-7edf4f942cca | id | |
| spl set id | 4df3fda6-0b29-420e-ab91-81441ce914ed | set_id | |
| unii | P88XT4IS4D | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: SEVERE MYELOSUPPRESSION Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3 [see Contraindications (4) ]. Monitor for neutropenia, which may be severe and result in infection or sepsis, it is recommended that frequent [see Warnings and Precautions (5.1 , 5.3) ]. Perform frequent complete blood cell counts on all patients receiving praclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Contraindications (4) , Warnings and Precautions (5.1 , 5.3) ]. WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning . Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3 . ( 4 ) Monitor for neutropenia, which may be severe and result in infection or sepsis. ( 5.1 , 5.3 ) Perform frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound). ( 5.1 , 5.3 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS Sensory neuropathy occurs frequently and may require dose reduction or treatment interruption. ( 5.2 ) Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1500 cells/mm 3 , then resume treatment at reduced dose levels. ( 5.3 ) Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. ( 5.4 ) Severe hypersensitivity reactions with fatal outcome have been reported. Do not re-challenge with this drug. ( 4 , 5.5 ) Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. ( 2.5 , 5.6 ) Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. ( 5.7 ) Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.8 , 8.1 , 8.3 ) 5.1 Severe Myelosuppression Severe myelosuppression (primarily neutropenia) is dose-dependent and a dose-limiting toxicity of paclitaxel protein-bound particles for injectable suspension (albumin-bound). In clinical studies, Grade 3-4 neutropenia occurred in 34% of patients with metastatic breast cancer (MBC), 47% of patients with non-small cell lung cancer (NSCLC), and 38% of patients with pancreatic cancer. Monitor for severe neutropenia and thrombocytopenia by performing complete blood cell counts frequently, including prior to dosing on Day 1 (for MBC) and Days 1, 8, and 15 (for NSCLC and for pancreatic cancer). Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) to patients with baseline absolute neutrophil counts (ANC) of less than 1,500 cells/mm 3 [see Contraindications (4) ] . In the case of severe neutropenia (<500 cells/mm 3 for seven days or more) during a course of paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy, reduce the dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in subsequent courses in patients with either MBC or NSCLC. In patients with MBC, resume treatment with every-3-week cycles of paclitaxel protein-bound particles for injectable suspension (albumin-bound) after ANC recovers to a level >1,500 cells/mm 3 and platelets recover to a level >100,000 cells/mm 3 . In patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly paclitaxel protein-bound particles for injectable suspension (albumin-bound) and every-3-week carboplatin after ANC recovers to at least 1500 cells/mm 3 and platelet count of at least 100,000 cells/mm 3 on Day 1 or to an ANC of at least 500 cells/mm 3 and platelet count of at least 50,000 cells/mm 3 on Days 8 or 15 of the cycle [see Dosage and Administration (2.6) ]. In patients with adenocarcinoma of the pancreas, withhold paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine if the ANC is less than 500 cells/mm 3 or platelets are less than 50,000 cells/mm 3 and delay initiation of the next cycle if the ANC is less than 1500 cells/mm 3 or platelet count is less than 100,000 cells/mm 3 on Day 1 of the cycle. Resume treatment with appropriate dose reduction if recommended [see Dosage and Administration (2.6) ]. 5.2 Severe Neuropathy Sensory neuropathy is dose-and schedule-dependent [ see Adverse Reactions ( 6.1 ) ]. If ≥ Grade 3 sensory neuropathy develops, withhold paclitaxel protein-bound particles for injectable suspension (albumin-bound) treatment until resolution to Grade 1 or 2 for metastatic breast cancer or until resolution to ≤ Grade 1 for NSCLC and pancreatic cancer followed by a dose reduction for all subsequent courses of paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Dosage and Administration (2.6) ]. 5.3 Sepsis Sepsis occurred in 5% of patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine. Biliary obstruction or presence of biliary stent were risk factors for severe or fatal sepsis. If a patient becomes febrile (regardless of ANC) initiate treatment with broad spectrum antibiotics. For febrile neutropenia, interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until fever resolves and ANC ≥ 1500, then resume treatment at reduced dose levels [see Dosage and Administration (2.6) ] . 5.4 Pneumonitis Pneumonitis, including some cases that were fatal, occurred in 4% of patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine. Monitor patients for signs and symptoms of pneumonitis and interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine during evaluation of suspected pneumonitis. After ruling out infectious etiology and upon making a diagnosis of pneumonitis, permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. 5.5 Severe Hypersensitivity Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, have been reported. Do not rechallenge patients who experience a severe hypersensitivity reaction to paclitaxel protein-bound particles for injectable suspension (albumin-bound) with this drug [see Contraindications (4) ] . Cross-hypersensitivity between paclitaxel protein-bound particles for injectable suspension (albumin-bound) and other taxane products has been reported and may include severe reactions such as anaphylaxis. Closely monitor patients with a previous history of hypersensitivity to other taxanes during initiation of paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy. 5.6 Use in Patients with Hepatic Impairment The exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment. Closely monitor patients with hepatic impairment for severe myelosuppression. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is not recommended in patients who have total bilirubin >5 x ULN or AST >10 x ULN. In addition, paclitaxel protein-bound particles for injectable suspension (albumin-bound) is not recommended in patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment (total bilirubin >1.5 x ULN and AST ≤10 x ULN). Reduce the starting dose for patients with moderate or severe hepatic impairment [see Dosage and Administration (2.5) , Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . 5.7 Albumin (Human) Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin (human), a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin. 5.8 Embryo-Fetal Toxicity Based on mechanism of action and findings in animals, paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of paclitaxel formulated as albumin-bound particles to rats during pregnancy at doses lower than the maximum recommended human dose, based on body surface area, caused embryo-fetal toxicities, including intrauterine mortality, increased resorptions, reduced numbers of live fetuses, and malformations. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception and avoid becoming pregnant during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and for at least six months after the last dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Use in Specific Populations (8.1 , 8.3) , Clinical Pharmacology (12.1) ]. Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception and avoid fathering a child during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and for at least three months after the last dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Use in Specific Populations (8.1 , 8.3) , Nonclinical Toxicology (13.1) ].
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table ID="table9" width="700"> <caption>Table 9: Selected Hematologic Laboratory-Detected Abnormalities with a Higher Incidence (≥ 5% for Grades 1-4 or ≥ 2% for Grades 3-4 Events) in the Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound)/Gemcitabine Arm</caption> <tfoot> <tr> <td colspan="5"> <sup>a</sup> 405 patients assessed in paclitaxel protein-bound particles for injectable suspension (albumin-bound)/gemcitabine-treated group.</td> </tr> <tr> <td colspan="5"> <sup>b</sup> 388 patients assessed in gemcitabine-treated group.</td> </tr> <tr> <td colspan="5"> <sup>c</sup> 404 patients assessed in paclitaxel protein-bound particles for injectable suspension (albumin-bound)/gemcitabine-treated group.</td> </tr> <tr> <td colspan="5"> <sup>d</sup> Neutrophil growth factors were administered to 26% of patients in the paclitaxel protein-bound particles for injectable suspension (albumin-bound)/gemcitabine group.</td> </tr> </tfoot> <tbody> <tr> <td styleCode="Botrule Lrule Rrule" rowspan="2"/> <td styleCode="Botrule Lrule Rrule" colspan="2" align="center"> <content styleCode="bold">Paclitaxel protein-bound particles for injectable suspension (albumin-bound) (125 mg/m<sup>2</sup>)/ Gemcitabine<sup>d</sup> </content> </td> <td styleCode="Botrule Lrule Rrule" colspan="2" align="center"> <content styleCode="bold">Gemcitabine</content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule" align="center"> <content styleCode="bold">Grades 1-4 (%) </content> </td> <td styleCode="Botrule Lrule Rrule" align="center"> <content styleCode="bold">Grade 3-4 (%) </content> </td> <td styleCode="Botrule Lrule Rrule" align="center"> <content styleCode="bold">Grades 1-4 (%) </content> </td> <td styleCode="Botrule Lrule Rrule" align="center"> <content styleCode="bold">Grade 3-4 (%) </content> </td> </tr> <tr> <td styleCode="Botrule Lrule Rrule">Neutropenia<sup>a,b</sup> </td> <td styleCode="Botrule Lrule Rrule" align="center">73</td> <td styleCode="Botrule Lrule Rrule" align="center">38</td> <td styleCode="Botrule Lrule Rrule" align="center">58</td> <td styleCode="Botrule Lrule Rrule" align="center">27</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule">Thrombocytopenia<sup>b,c</sup> </td> <td styleCode="Botrule Lrule Rrule" align="center">74</td> <td styleCode="Botrule Lrule Rrule" align="center">13</td> <td styleCode="Botrule Lrule Rrule" align="center">70</td> <td styleCode="Botrule Lrule Rrule" align="center">9</td> </tr> </tbody> </table>
adverse reactions table
<table ID="table10" width="900"> <caption>Table 10: Selected Adverse Reactions with a Higher Incidence (≥5% for All Grade Toxicity or ≥2% for Grade 3 or Higher Toxicity) in the Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound)/Gemcitabine Arm </caption> <tfoot> <tr> <td colspan="6"> <sup>a</sup> Peripheral neuropathy is defined by the MedDRA Version 15.0 Standard MedDRA Query neuropathy (broad scope).</td> </tr> <tr> <td colspan="6"> <sup>b</sup> Urinary tract infections includes the preferred terms of: urinary tract infection, cystitis, urosepsis, urinary tract infection bacterial, and urinary tract infection enterococcal.</td> </tr> </tfoot> <tbody> <tr> <td styleCode="Botrule Lrule Rrule" rowspan="2" align="left" valign="bottom"> <content styleCode="bold">System Organ Class</content> </td> <td styleCode="Botrule Lrule Rrule" rowspan="2" valign="bottom"> <content styleCode="bold">Adverse Reaction</content> </td> <td styleCode="Botrule Rrule" colspan="2" align="center"> <content styleCode="bold">Paclitaxel protein-bound particles for injectable suspension (albumin-bound) (125 mg/m<sup>2</sup>) and gemcitabine (N=421)</content> </td> <td styleCode="Botrule Rrule" colspan="2" align="center" valign="top"> <content styleCode="bold">Gemcitabine (N=402)</content> </td> </tr> <tr> <td styleCode="Botrule Rrule" align="center" valign="bottom"> <content styleCode="bold">All Grades</content> </td> <td styleCode="Botrule Rrule" align="center"> <content styleCode="bold">Grade 3 or Higher</content> </td> <td styleCode="Botrule Rrule" align="center" valign="bottom"> <content styleCode="bold">All Grades</content> </td> <td styleCode="Botrule Rrule" align="center"> <content styleCode="bold">Grade 3 or Higher</content> </td> </tr> <tr> <td styleCode="Lrule Rrule" rowspan="2">General disorders and administration site conditions</td> <td styleCode="Botrule Lrule Rrule" valign="top">Fatigue</td> <td styleCode="Botrule Lrule Rrule" align="center">248 (59%)</td> <td styleCode="Botrule Lrule Rrule" align="center">77 (18%)</td> <td styleCode="Botrule Lrule Rrule" align="center">183 (46%)</td> <td styleCode="Botrule Lrule Rrule" align="center">37 (9%)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule">Peripheral edema</td> <td styleCode="Botrule Lrule Rrule" align="center">194 (46%)</td> <td styleCode="Botrule Lrule Rrule" align="center">13 (3%)</td> <td styleCode="Botrule Lrule Rrule" align="center">122 (30%)</td> <td styleCode="Botrule Lrule Rrule" align="center">12 (3%)</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Pyrexia</td> <td styleCode="Botrule Lrule Rrule" align="center">171 (41%)</td> <td styleCode="Botrule Lrule Rrule" align="center">12 (3%)</td> <td styleCode="Botrule Lrule Rrule" align="center">114 (28%)</td> <td styleCode="Botrule Lrule Rrule" align="center">4 (1%)</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Asthenia</td> <td styleCode="Botrule Lrule Rrule" align="center">79 (19%)</td> <td styleCode="Botrule Lrule Rrule" align="center">29 (7%)</td> <td styleCode="Botrule Lrule Rrule" align="center">54 (13%)</td> <td styleCode="Botrule Lrule Rrule" align="center">17 (4%)</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Mucositis</td> <td styleCode="Botrule Lrule Rrule" align="center">42 (10%)</td> <td styleCode="Botrule Lrule Rrule" align="center">6 (1%)</td> <td styleCode="Botrule Lrule Rrule" align="center">16 (4%)</td> <td styleCode="Botrule Lrule Rrule" align="center">1 (<1%)</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Gastrointestinal disorders</td> <td styleCode="Botrule Lrule Rrule">Nausea</td> <td styleCode="Botrule Lrule Rrule" align="center">228 (54%)</td> <td styleCode="Botrule Lrule Rrule" align="center">27 (6%)</td> <td styleCode="Botrule Lrule Rrule" align="center">192 (48%)</td> <td styleCode="Botrule Lrule Rrule" align="center">14 (3%)</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Diarrhea</td> <td styleCode="Botrule Lrule Rrule" align="center">184 (44%)</td> <td styleCode="Botrule Lrule Rrule" align="center">26 (6%)</td> <td styleCode="Botrule Lrule Rrule" align="center">95 (24%)</td> <td styleCode="Botrule Lrule Rrule" align="center">6 (1%)</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Vomiting</td> <td styleCode="Botrule Lrule Rrule" align="center">151 (36%)</td> <td styleCode="Botrule Lrule Rrule" align="center">25 (6%)</td> <td styleCode="Botrule Lrule Rrule" align="center">113 (28%)</td> <td styleCode="Botrule Lrule Rrule" align="center">15 (4%)</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule" rowspan="2">Skin and subcutaneous tissue disorders</td> <td styleCode="Botrule Lrule Rrule" valign="top">Alopecia</td> <td styleCode="Botrule Lrule Rrule" align="center">212 (50%)</td> <td styleCode="Botrule Lrule Rrule" align="center">6 (1%)</td> <td styleCode="Botrule Lrule Rrule" align="center">21 (5%)</td> <td styleCode="Botrule Lrule Rrule" align="center">0</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule">Rash</td> <td styleCode="Botrule Lrule Rrule" align="center">128 (30%)</td> <td styleCode="Botrule Lrule Rrule" align="center">8 (2%)</td> <td styleCode="Botrule Lrule Rrule" align="center">45 (11%)</td> <td styleCode="Botrule Lrule Rrule" align="center">2 (<1%)</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Nervous system disorders</td> <td styleCode="Botrule Lrule Rrule">Peripheral neuropathy<sup>a</sup> </td> <td styleCode="Botrule Lrule Rrule" align="center">227 (54%)</td> <td styleCode="Botrule Lrule Rrule" align="center">70 (17%)</td> <td styleCode="Botrule Lrule Rrule" align="center">51 (13%)</td> <td styleCode="Botrule Lrule Rrule" align="center">3 (1%)</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Dysgeusia</td> <td styleCode="Botrule Lrule Rrule" align="center">68 (16%)</td> <td styleCode="Botrule Lrule Rrule" align="center">0</td> <td styleCode="Botrule Lrule Rrule" align="center">33 (8%)</td> <td styleCode="Botrule Lrule Rrule" align="center">0</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Headache</td> <td styleCode="Botrule Lrule Rrule" align="center">60 (14%)</td> <td styleCode="Botrule Lrule Rrule" align="center">1 (<1%)</td> <td styleCode="Botrule Lrule Rrule" align="center">38 (9%)</td> <td styleCode="Botrule Lrule Rrule" align="center">1 (<1%)</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule" rowspan="2">Metabolism and nutrition disorders</td> <td styleCode="Botrule Lrule Rrule" valign="top">Decreased appetite</td> <td styleCode="Botrule Lrule Rrule" align="center">152 (36%)</td> <td styleCode="Botrule Lrule Rrule" align="center">23 (5%)</td> <td styleCode="Botrule Lrule Rrule" align="center">104 (26%)</td> <td styleCode="Botrule Lrule Rrule" align="center">8 (2%)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule">Dehydration</td> <td styleCode="Botrule Lrule Rrule" align="center">87 (21%)</td> <td styleCode="Botrule Lrule Rrule" align="center">31 (7%)</td> <td styleCode="Botrule Lrule Rrule" align="center">45 (11%)</td> <td styleCode="Botrule Lrule Rrule" align="center">10 (2%)</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Hypokalemia</td> <td styleCode="Botrule Lrule Rrule" align="center">52 (12%)</td> <td styleCode="Botrule Lrule Rrule" align="center">18 (4%)</td> <td styleCode="Botrule Lrule Rrule" align="center">28 (7%)</td> <td styleCode="Botrule Lrule Rrule" align="center">6 (1%)</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule" rowspan="2">Respiratory, thoracic and mediastinal disorders</td> <td styleCode="Botrule Lrule Rrule" valign="top">Cough</td> <td styleCode="Botrule Lrule Rrule" align="center">72 (17%)</td> <td styleCode="Botrule Lrule Rrule" align="center">0</td> <td styleCode="Botrule Lrule Rrule" align="center">30 (7%)</td> <td styleCode="Botrule Lrule Rrule" align="center">0</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule">Epistaxis</td> <td styleCode="Botrule Lrule Rrule" align="center">64 (15%)</td> <td styleCode="Botrule Lrule Rrule" align="center">1 (<1%)</td> <td styleCode="Botrule Lrule Rrule" align="center">14 (3%)</td> <td styleCode="Botrule Lrule Rrule" align="center">1 (<1%)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule Toprule">Infections and infestations</td> <td styleCode="Botrule Lrule Rrule">Urinary tract infections <sup>b</sup> </td> <td styleCode="Botrule Lrule Rrule" align="center">47 (11%)</td> <td styleCode="Botrule Lrule Rrule" align="center">10 (2%)</td> <td styleCode="Botrule Lrule Rrule" align="center">20 (5%)</td> <td styleCode="Botrule Lrule Rrule" align="center">1 (<1%)</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule" rowspan="2" valign="top">Musculoskeletal and connective tissue disorders</td> <td styleCode="Botrule Lrule Rrule" valign="top">Pain in extremity</td> <td styleCode="Botrule Lrule Rrule" align="center">48 (11%)</td> <td styleCode="Botrule Lrule Rrule" align="center">3 (1%)</td> <td styleCode="Botrule Lrule Rrule" align="center">24 (6%)</td> <td styleCode="Botrule Lrule Rrule" align="center">3 (1%)</td> </tr> <tr> <td styleCode="Botrule Lrule Rrule">Arthralgia</td> <td styleCode="Botrule Lrule Rrule" align="center">47 (11%)</td> <td styleCode="Botrule Lrule Rrule" align="center">3 (1%)</td> <td styleCode="Botrule Lrule Rrule" align="center">13 (3%)</td> <td styleCode="Botrule Lrule Rrule" align="center">1 (<1%)</td> </tr> <tr> <td styleCode="Lrule"/> <td styleCode="Botrule Lrule Rrule">Myalgia</td> <td styleCode="Botrule Lrule Rrule" align="center">44 (10%)</td> <td styleCode="Botrule Lrule Rrule" align="center">4 (1%)</td> <td styleCode="Botrule Lrule Rrule" align="center">15 (4%)</td> <td styleCode="Botrule Lrule Rrule" align="center">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Psychiatric disorders</td> <td styleCode="Botrule Lrule Rrule">Depression</td> <td styleCode="Botrule Lrule Rrule" align="center">51 (12%)</td> <td styleCode="Botrule Lrule Rrule" align="center">1 (<1%)</td> <td styleCode="Botrule Lrule Rrule" align="center">24 (6%)</td> <td styleCode="Botrule Lrule Rrule" align="center">0</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.